Dr Reddy’s Laboratories Ltd launched the US Food and Drug Administration (FDA) approved ziprasidone mesylate for injection, 20 mg (base)/mL single-dose vials, the therapeutic generic equivalent of Geodon (ziprasidone mesylate) injection, 20 mg/mL in US market .
“We’re pleased to bring the first generic of ziprasidone mesylate for Injection to market for patients who will benefit from access to affordable medicine. With every new product launch, we believe we are making healthcare more affordable by delivering value to the pharmacy,” explains Marc Kikuchi, chief executive officer, North America Generics, Dr. Reddy’s Laboratories.
Also read: US gives first shot to person in experimental COVID-19 vaccine test
“This is a great addition to our injectable offering in the US market as we continue to augment our portfolio and drive growth within the hospital segment,” Kikuchi added.
The Geodon brand had US sales of approximately $21.8 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone mesylate for injection is not approved for the treatment of patients with dementia related psychosis.
